Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at RBC Capital
August 7, 2024 6:24 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $29.00) while maintaining a Outperform rating.
The analyst comments "Daybue miss representative of launch growing pains, in our view, as new patient starts fall short of Street (and even... More
